Study: Remdesivir may protect kidney transplants after COVID-19

Early remdesivir given within a week of COVID-19 diagnosis was linked to lower risks of graft loss and heart complications over the following year in adult kidney transplant recipients, according to a Johns Hopkins target trial emulation study in JAMA Network Open. The findings may ease clinician hesitation about using the antiviral when it is clinically appropriate for this high-risk group.

Key Takeaways

• Among 432 adult kidney transplant recipients with COVID-19, early remdesivir was tied to a 47% lower risk of all-cause graft loss.
• The same treatment window was associated with a 42% lower risk of cardiovascular events up to one year later.
• Patients received at least three consecutive days of intravenous remdesivir within seven days of diagnosis.
• Death and long COVID trends were less clear; long COVID numbers were too small for firm conclusions.
• Researchers say timely antiviral care may help beyond the acute COVID-19 phase in transplant patients.

What did the remdesivir study find?

Investigators reviewed adult kidney transplant recipients diagnosed with COVID-19 between March 2020 and January 2024 at five Johns Hopkins Medicine hospitals in Maryland. Of 432 patients, 177 (41%) got remdesivir for at least three days within a week of diagnosis; 255 (59%) did not. People who received monoclonal antibodies or other antivirals were excluded.

All patients were followed for up to a year. The main endpoint was all-cause graft loss—transplant rejection or death from any cause. Secondary outcomes included cardiovascular complications, death, and long COVID.

Overall, 48 patients (11%) had all-cause graft loss, 43 (10%) had a cardiovascular event such as heart attack, stroke, or cardiac-related death, 35 (8%) died from any cause, and 17 (4%) had documented long COVID. After adjusting for age, other illnesses, medications, disease severity, transplant timing, vaccination, and diagnosis date, early remdesivir was linked to those 47% and 42% risk reductions.

Trends suggested fewer deaths with remdesivir, but the association was not statistically significant. The long COVID analysis was inconclusive because few patients had that diagnosis recorded. More unexpected medical headlines also appear in our Bizarre News & Florida Man coverage.

Why does early remdesivir matter for transplant patients?

Kidney transplant recipients face layered risks: weak immune defenses, immunosuppressive drugs, possible drug interactions, and fragile kidney function. Senior author Nitipong Permpalung, M.D., M.P.H., associate director of the Johns Hopkins Transplant Research Center, said the results suggest timely antiviral treatment may bring benefits beyond the acute phase of COVID-19 and could reduce physician hesitation when remdesivir is appropriate.

Short-term antiviral benefits for higher-risk COVID-19 patients are already known. This study stands out as one of the largest to report longer-term outcomes in adult kidney transplant recipients, a group often left out of randomized trials because of underlying risk. Full study details are available via Medical Xpress and the JAMA Network Open publication.

Who was in the study, and what are the caveats?

Many participants already had serious health burdens. Twenty percent needed supplemental oxygen at diagnosis; 95% had high blood pressure, 46% had diabetes, and 15% had coronary artery disease. About one in four had received a kidney transplant within the year before COVID-19. More than half stopped an immunosuppressive drug meant to prevent rejection when they were diagnosed.

Most infections (60%) occurred during Omicron circulation after Dec. 15, 2021. More than half of participants had received at least one COVID-19 vaccine dose. Remdesivir recipients were older (median age 61 vs. 54) and more often needed breathing help (33% vs. 11%), yet still showed better adjusted graft and heart outcomes.

First author Karan Srisurapanont, M.D., said early viral suppression may cut systemic inflammation, vessel injury, and clotting problems that can harm the heart and kidney. The design was a target trial emulation, not a randomized trial, so residual confounding remains possible. Clinicians still weigh immune status, kidney health, drug interactions, side effects, and COVID-19 timing and severity before choosing therapy.